Related Experiment Video

Updated: May 31, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Targeting angiogenesis in ovarian cancer

Jordan Schmitt1, Daniela Matei

  • 1Department of Medicine, Indiana University School of Medicine, Indianapolis, 46202, United States.

Cancer Treatment Reviews
|July 19, 2011
PubMed

Insights

Targeting angiogenesis, crucial for ovarian cancer growth and spread, offers a promising new treatment. Antiangiogenic therapies are emerging as a key strategy to overcome drug resistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Ovarian cancer chemotherapy resistance leads to recurrence.
  • Tumor progression relies on angiogenesis, regulated by growth factors.
  • Targeting key signaling pathways is a novel therapeutic strategy.

Purpose of the Study:

  • To review preclinical evidence for inhibiting angiogenesis in ovarian cancer.
  • To provide an overview of clinical development for antiangiogenic agents.
  • To highlight the potential of antiangiogenic therapy in difficult-to-treat ovarian cancer.

Main Methods:

  • Review of preclinical studies on angiogenesis pathways.
  • Analysis of clinical trial data for antiangiogenic agents.
  • Discussion of combination therapies with chemotherapy.

Main Results:

  • Preclinical data support the rationale for targeting angiogenesis.
  • Clinical trials are evaluating antiangiogenic agents alone and with chemotherapy.
  • Early results indicate significant potential for antiangiogenic therapy.

Conclusions:

  • Inhibiting angiogenesis pathways is a promising approach for ovarian cancer.
  • Antiangiogenic therapy represents a potential paradigm shift in treatment.
  • Further clinical evaluation is ongoing to establish efficacy.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...